Buy tricor and fenofibrate online

Although Abbott Laboratories have reached a deal with generic drug maker Teva for the rights to cholesterol drug TriCor, stipulations could push back the release of generic TriCor till July of 2012. This is bad news for those who were looking forward to a cheaper version of the drug being released soon.

Abbott has a track record of abusing the system in order to delay generic competition. According to CNN Money,

Abbott and Fournier were sued earlier this decade for alleged abuse of the patent system to ward off competition for TriCor from generic drug makers. Among the plaintiffs in the antitrust action was Impax Laboratories Inc. (IPXL). The generic-drug maker a month ago said it began a challenge of TriCor patents.

The deal with Teva results in litigation between the two companies being dropped. Abbott spokesman Kelly Morrison said the agreement “allows Abbott to maintain certainty” about when generic competition begins.

Abbott has been abusing the system since the 1960’s when the generic version of TriCor known as fenofibrate was discovered by a French company and began selling the drug throughout Europe in 1975. Abbott discovered this, and licensed it in the late 90’s. When the original patent ran out, Abbott patented a new way to make it, holding off generic drug production and protecting profits.

Once again, Abbott is trying to keep American consumers from receiving TriCor at a lower more reasonable price, you can easily buy TriCor online much cheaper here, at No Prescription Needed.

The large American drug maker Abbott Laboratories is moving to close a deal today to purchase the prescription drug unit of the Belgian company Solvay for close to $6.6 billion in order to take sole possession of a shared cholesterol drug venture. The deal could possibly pay out an addition $440 million if the product meets certain sales goals from 2011 to 2013.

The deal will also give Abbott sole possession TriCor, which competes with Antara and Lofibra in the highly competitive cholesterol drug market. Last year TriCor had over $1.3 billion in sales.

In addition to TriCor, Abbott will also receive full ownership of Solvay’s drugs for hormone replacement, hypertension, as well as other neurological conditions.

According to the New York Times,

Pending health care legislation in Congress is not considered a deterrent for pharmaceutical acquisitions, because the drug makers are expected to do well in whatever emerges from Washington. The industry has a potentially winning political argument that its drugs prevent disease and save medical costs. And the industry stands to benefit from the addition of tens of millions of Americans to the ranks of the insured, under a health care overhaul.

Abbott’s patent on TriCor is set to expire soon, which means generic, less expensive versions of TriCor will be available. Abbott will then face the challenge of switching consumers over to the new drug Trilipix. This means that Abbott will throw all of it’s marketing behind Trilipix, and try and dupe consumers into buying a medication that is no more affective, yet much more expensive.